Results 11 to 20 of about 46,090 (276)

Diagnostic Microdosing Approach to Study Gemcitabine Resistance [PDF]

Chemical Research in Toxicology, 2016
Gemcitabine metabolites cause the termination of DNA replication and induction of apoptosis. We determined whether subtherapeutic "microdoses" of gemcitabine are incorporated into DNA at levels that correlate to drug cytotoxicity. A pair of nearly isogenic bladder cancer cell lines differing in resistance to several chemotherapy drugs were treated with
Scharadin, Tiffany M, Zhang, Hongyong, Zimmermann, Maike, Wang, Sisi, Malfatti, Michael A, Cimino, George D, Turteltaub, Kenneth, de Vere White, Ralph, Pan, Chong-xian, Henderson, Paul T   +9 more
openaire   +6 more sources

Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma

Cancer Biology & Medicine, 2023
Objective: Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant gastrointestinal cancer with a 5-year survival rate of only 9%. Of PDAC patients, 15%-20% are eligible for radical surgery.
Danqi Fu, Jingrui Yan, Zhaoyu Zhang, Yang Liu, Xiaoqing Ma, Jinsheng Ding, Shengyu Yang, Ran Zhao, Antao Chang, Chuntao Gao, Jing Liu, Tiansuo Zhao, Xiuchao Wang, Chongbiao Huang, Song Gao, Ying Ma, Bo Tang, Yukuan Feng, Hongwei Wang, Jihui Hao   +19 more
doaj   +2 more sources

DNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cells. [PDF]

PLoS ONE, 2012
BACKGROUND: Down regulation of genes coding for nucleoside transporters and drug metabolism responsible for uptake and metabolic activation of the nucleoside gemcitabine is related with acquired tumor resistance against this agent.
Myrna Candelaria, Erick de la Cruz-Hernandez, Lucia Taja-Chayeb, Enrique Perez-Cardenas, Catalina Trejo-Becerril, Aurora Gonzalez-Fierro, Alma Chavez-Blanco, Ernesto Soto-Reyes, Guadalupe Dominguez, Jaenai E Trujillo, Jose Diaz-Chavez, Alfonso Duenas-Gonzalez   +11 more
doaj   +2 more sources

Possible Role of Cytochrome P450 1B1 in the Mechanism of Gemcitabine Resistance in Pancreatic Cancer

Biomedicines, 2021
Patient-derived xenograft models reportedly represent original tumor morphology and gene mutation profiles. In addition, patient-derived xenografts are expected to recapitulate the parental tumor drug responses.
Erica Yada, Rika Kasajima, Atsushi Niida, Seiya Imoto, Satoru Miyano, Yohei Miyagi, Tetsuro Sasada, Satoshi Wada   +7 more
doaj   +2 more sources

Resistance to Gemcitabine in Pancreatic Cancer Is Connected to Methylglyoxal Stress and Heat Shock Response [PDF]

Cells, 2023
Pancreatic ductal adenocarcinoma (PDAC) is a fatal disease with poor prognosis. Gemcitabine is the first-line therapy for PDAC, but gemcitabine resistance is a major impediment to achieving satisfactory clinical outcomes.
Rebekah Crake, Imène Gasmi, Jordan Dehaye, Fanny Lardinois, Raphaël Peiffer, Naïma Maloujahmoum, Ferman Agirman, Benjamin Koopmansch, Nicky D’Haene, Oier Azurmendi Senar, Tatjana Arsenijevic, Frédéric Lambert, Olivier Peulen, Jean-Luc Van Laethem, Akeila Bellahcène   +14 more
doaj   +2 more sources

CUB domain-containing protein 1 signaling dysregulates gemcitabine metabolism contributing to therapeutic resistance in T24 cells.

PLoS ONE
Gemcitabine is commonly used in the standard first-line treatment of urothelial carcinoma (UC); however, the emergence of drug resistance significantly limits its clinical benefit.
Kun-Lin Hsieh, Kuan-Hua Huang, Ching-Ping Chang, Hung-Wen Tsai, Yu-Hao Chang, Yi-Ru Zheng, Huei-Sheng Huang   +6 more
doaj   +2 more sources

The complement C3a/C3aR pathway is associated with treatment resistance to gemcitabine-based neoadjuvant therapy in pancreatic cancer

Computational and Structural Biotechnology Journal
Gemcitabine is a standard first-line drug for pancreatic cancer chemotherapy. Nevertheless, gemcitabine resistance is common and significantly limits its therapeutic efficacy, impeding advancements in pancreatic cancer treatment. In this study, through a
Saimeng Shi, Longyun Ye, Kaizhou Jin, Xianjun Yu, Duancheng Guo, Weiding Wu   +5 more
doaj   +2 more sources

Resistance mechanisms to gemcitabine in pancreatic cancer [PDF]

, 2021
Treatment of pancreatic cancer involves combinations of therapeutics including use of the chemotherapy agent gemcitabine. This thesis aimed to identify gemcitabine resistance mechanisms in pancreatic cancer and so enable discovery of biomarkers to tailor chemotherapy.
Mann, Kulbir
openaire   +2 more sources

Targeting ketone body metabolism in mitigating gemcitabine resistance [PDF]

JCI Insight
Chemotherapy is often combined with surgery for muscle invasive and nonmuscle invasive bladder cancer (BCa). However, 70% of the patients recur within 5 years. Metabolic reprogramming is an emerging hallmark in cancer chemoresistance. Here, we report a gemcitabine resistance mechanism that promotes cancer reprogramming via the metabolic enzyme OXCT1 ...
Krizia Rohena-Rivera, Sungyong You, Minhyung Kim, Sandrine Billet, Johanna ten Hoeve, Gabrielle Gonzales, Chengqun Huang, Ashley Heard, Keith Syson Chan, Neil A. Bhowmick   +9 more
openaire   +3 more sources

TRIM59/RBPJ positive feedback circuit confers gemcitabine resistance in pancreatic cancer by activating the Notch signaling pathway [PDF]

Cell Death and Disease
Pancreatic cancer (PC) is one of the most lethal malignant tumors that lacks effective treatment, and gemcitabine-based chemoresistance occurs frequently. Therefore, new therapeutic strategies for PC are urgently needed.
Shiyu Chen, Zhiwei He, Kun Cai, Yan Zhang, Hongyan Zhu, Chong Pang, Jiaqi Zhang, Dong Wang, Xundi Xu   +8 more
doaj   +2 more sources